NasdaqGS:ALXN

Stock Analysis Report

Executive Summary

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes various therapeutic products.

Snowflake

Fundamentals

Excellent balance sheet and good value.

Risks

  • Alexion Pharmaceuticals has significant price volatility in the past 3 months.

Similar Companies

Share Price & News

How has Alexion Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-1.6%

ALXN

-0.5%

US Biotechs

-0.02%

US Market


1 Year Return

-13.4%

ALXN

-11.3%

US Biotechs

1.6%

US Market

ALXN underperformed the Biotechs industry which returned -11.3% over the past year.

ALXN underperformed the Market in United States of America which returned 1.6% over the past year.


Share holder returns

ALXNIndustryMarket
7 Day-1.6%-0.5%-0.02%
30 Day-8.0%-2.1%2.7%
90 Day-20.2%-1.9%1.4%
1 Year-13.4%-13.4%-10.6%-11.3%3.8%1.6%
3 Year-16.9%-16.9%4.6%1.1%45.2%35.8%
5 Year-37.0%-37.0%1.9%-3.0%61.8%44.1%

Price Volatility Vs. Market

How volatile is Alexion Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

2 weeks ago | Simply Wall St

Introducing Alexion Pharmaceuticals (NASDAQ:ALXN), The Stock That Dropped 32% In The Last Five Years

Valuation

Is Alexion Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

38%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Alexion Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).

Alexion Pharmaceuticals's share price is below the future cash flow value, but not at a substantial discount (< 40%).


Price Based on Earnings

Alexion Pharmaceuticals is good value based on earnings compared to the US Biotechs industry average.

Alexion Pharmaceuticals is good value based on earnings compared to the United States of America market.


Price Based on Expected Growth

Alexion Pharmaceuticals is poor value based on expected growth next year.


Price Based on Value of Assets

Alexion Pharmaceuticals is good value based on assets compared to the US Biotechs industry average.


Next Steps

Future Growth

How is Alexion Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 19 analysts?

11.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Alexion Pharmaceuticals's revenue is expected to grow by 9.5% yearly, however this is not considered high growth (20% yearly).

Alexion Pharmaceuticals's earnings are expected to grow by 11.4% yearly, however this is not considered high growth (20% yearly).

Alexion Pharmaceuticals's revenue growth is expected to exceed the United States of America market average.

Alexion Pharmaceuticals's earnings growth is positive but not above the United States of America market average.

Alexion Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Alexion Pharmaceuticals is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).


Next Steps

Past Performance

How has Alexion Pharmaceuticals performed over the past 5 years?

2.0%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Alexion Pharmaceuticals's year on year earnings growth rate has been positive over the past 5 years.

Alexion Pharmaceuticals has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.

Alexion Pharmaceuticals has become profitable in the last year making it difficult to compare the US Biotechs industry average.


Return on Equity

Alexion Pharmaceuticals has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

Alexion Pharmaceuticals used its assets less efficiently than the US Biotechs industry average last year based on Return on Assets.


Return on Capital Employed

Alexion Pharmaceuticals has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is Alexion Pharmaceuticals's financial position?


Financial Position Analysis

Alexion Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Alexion Pharmaceuticals's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Alexion Pharmaceuticals's level of debt (25.9%) compared to net worth is satisfactory (less than 40%).

The level of debt compared to net worth has increased over the past 5 years (2.8% vs 25.9% today).

Debt is well covered by operating cash flow (54.8%, greater than 20% of total debt).

Interest payments on debt are well covered by earnings (EBIT is 17.6x coverage).


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 1.6x debt.


Next Steps

Dividend

What is Alexion Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Alexion Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Alexion Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Alexion Pharmaceuticals has not reported any payouts.

Unable to verify if Alexion Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Alexion Pharmaceuticals has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of Alexion Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of Alexion Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

2.3yrs

Average management tenure


CEO

Ludwig Hantson (56yo)

2.5yrs

Tenure

US$16,490,250

Compensation

Dr. Ludwig N. Hantson, Ph.D., has been Chief Executive Officer at Alexion Pharmaceuticals, Inc. since March 27, 2017. Dr. Hantson has been the President of Synovis Life Technologies Inc. since February 14, ...


CEO Compensation Analysis

Ludwig's remuneration is higher than average for companies of similar size in United States of America.

Ludwig's compensation has increased in line with Alexion Pharmaceuticals recently becoming profitable.


Management Age and Tenure

2.3yrs

Average Tenure

56yo

Average Age

The tenure for the Alexion Pharmaceuticals management team is about average.


Board Age and Tenure

2.4yrs

Average Tenure

62.5yo

Average Age

The average tenure for the Alexion Pharmaceuticals board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

SellUS$37,123,46430 May 19
Baker Bros. Advisors LP
EntityCompany
Shares300,000
Max PriceUS$127.06
SellUS$252,00020 Feb 19
Daniel Bazarko
EntityIndividual
Role
Chief Accounting Officer
Chief Accounting Officer & Senior VP
Shares2,000
Max PriceUS$126.00
SellUS$310,93703 Jan 19
Ludwig Hantson
EntityIndividual
Role
Chief Executive Officer
CEO & Director
Shares3,244
Max PriceUS$95.85
SellUS$307,72930 Nov 18
Indrani M. Franchini
EntityIndividual
Role
Chief Compliance Officer
Executive VP & Chief Compliance Officer
Shares2,605
Max PriceUS$118.13

Ownership Breakdown


Management Team

  • Ellen Chiniara (60yo)

    Executive VP

    • Tenure: 1.6yrs
  • Ludwig Hantson (56yo)

    CEO & Director

    • Tenure: 2.5yrs
    • Compensation: US$16.49m
  • John Orloff (62yo)

    Executive VP and Head of Research & Development

    • Tenure: 2.3yrs
    • Compensation: US$4.86m
  • Paul Clancy (57yo)

    Executive VP & CFO

    • Tenure: 2.2yrs
    • Compensation: US$5.49m
  • Anne-Marie Law (52yo)

    Executive VP and Chief Patient & Employee Experience Officer

    • Tenure: 2.3yrs
    • Compensation: US$5.30m
  • Brian Goff (50yo)

    Executive VP & Chief Commercial Officer

    • Tenure: 2.3yrs
    • Compensation: US$4.88m
  • Indrani M. Franchini (47yo)

    Executive VP & Chief Compliance Officer

    • Tenure: 2.3yrs
  • Daniel Bazarko

    Chief Accounting Officer & Senior VP

    • Tenure: 0yrs
  • Susan Altschuller

    Vice President of Investor Relations

    • Tenure: 0yrs
  • Megan Goulart

    Senior Director of Corporate Communications

    • Tenure: 0yrs

Board Members

  • Felix Baker (50yo)

    Director

    • Tenure: 4.3yrs
    • Compensation: US$373.86k
  • Paul Friedman (76yo)

    Director

    • Tenure: 2yrs
    • Compensation: US$348.86k
  • Chris Coughlin (67yo)

    Director

    • Tenure: 5.2yrs
    • Compensation: US$533.86k
  • Deborah Dunsire (57yo)

    Independent Director

    • Tenure: 1.7yrs
    • Compensation: US$582.96k
  • David Brennan (65yo)

    Independent Chairman of the Board

    • Tenure: 2.3yrs
    • Compensation: US$448.86k
  • Judy Reinsdorf (55yo)

    Director

    • Tenure: 1.6yrs
    • Compensation: US$595.45k
  • Ludwig Hantson (56yo)

    CEO & Director

    • Tenure: 2.5yrs
    • Compensation: US$16.49m
  • Andreas Rummelt (63yo)

    Director

    • Tenure: 9.6yrs
    • Compensation: US$348.86k
  • Jack Mollen (68yo)

    Director

    • Tenure: 5.4yrs
    • Compensation: US$373.86k
  • Francois Nader (62yo)

    Director

    • Tenure: 1.8yrs
    • Compensation: US$348.86k

Company Information

Alexion Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Alexion Pharmaceuticals, Inc.
  • Ticker: ALXN
  • Exchange: NasdaqGS
  • Founded: 1992
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$23.694b
  • Shares outstanding: 224.23m
  • Website: https://www.alexion.com

Number of Employees


Location

  • Alexion Pharmaceuticals, Inc.
  • 121 Seaport Boulevard
  • Boston
  • Massachusetts
  • 2210
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ALXNNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDFeb 1996
AXPXTRA (XETRA Trading Platform)YesCommon StockDEEURFeb 1996
AXPDB (Deutsche Boerse AG)YesCommon StockDEEURFeb 1996
0QZMLSE (London Stock Exchange)YesCommon StockGBUSDFeb 1996
ALXN *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNFeb 1996
ALXNWBAG (Wiener Boerse AG)YesCommon StockATEURFeb 1996

Biography

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/20 00:08
End of Day Share Price2019/09/19 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.